Table 3 Changes in RT plan in studies assessing effect of PSMA PET results on treatment plan
Author and year | N | Inclusion criteria | Median PSA level, ng/mL (range) | Change in planned pelvic RT | ||
|---|---|---|---|---|---|---|
% local plan change | % extra-pelvic disease | local plan change details | ||||
Calais et al. 2018 [54] | 73 | IR/HR PCa prior to RT planning | 13.9 (0.22–909) | 7–19.5%a | 9.5% | covered pelvic LNs detected |
Frenzel et al. 2018 [51] | 20 | PCa prior to RT planning | 7.1 (0.48–137) | 15% | N/A | shifted from IR to HR, one patient had boost to distant PET findings |
Hruby et al. 2018 [55] | 109 | IR/HR PCa prior to RT planning | 9.9 (1.23–240) | 14.7% | 6.4% | covered pelvic LNs detected |
Roach et al. 2017 [44] | 108 | IR/HR PCa prior to RP/ EBRT/ systemic treatment | 8.6 (0.18–120) | 15% | 9% | higher dose and volume |
Sterzing et al. 2016 [62] | 15 | HR PCa for staging | 7 (0.28–45) | 13% | N/A | covered pelvic LNs detected |